Breaking News Instant updates and real-time market news.

GWPH

GW Pharmaceuticals

$162.57

-4.54 (-2.72%)

21:15
10/02/18
10/02
21:15
10/02/18
21:15

GW Pharmaceuticals 1.9M share Secondary priced at $158.00

Goldman Sachs, Morgan Stanley, JPMorgan and Cowen acted as joint book running managers for the offering.

  • 03

    Oct

GWPH GW Pharmaceuticals
$162.57

-4.54 (-2.72%)

09/07/18
MSCO
09/07/18
INITIATION
Target $197
MSCO
Overweight
GW Pharmaceuticals resumed with an Overweight at Morgan Stanley
Morgan Stanley analyst David Lebowitz resumed coverage of GW Pharmaceuticals with an Overweight rating and $197 price target, stating that he expects a strong launch for Epidiolex for Dravet and Lenox-Gastaut syndromes once the DEA has officially rescheduled the marijuana-based therapy as being acceptable for medicinal use. He projects 2019 Epidiolex franchise sales of $72M growing to $1.3B by 2025, Lebowitz tells investors.
09/19/18
MSCO
09/19/18
NO CHANGE
Target $197
MSCO
Overweight
Launch of GW Pharmaceuticals' Epidiolex 'likely imminent,' says Morgan Stanley
Morgan Stanley analyst David Lebowitz noted that the FDA approved GW Pharmaceuticals' cannabis-based Epidiolex for the treatment of two ultra rare forms of epilepsy on June 25 and the Drug Enforcement Agency rescheduling of the therapy to allow medicinal use was expected to take place within 90 days, or by about September 23. He sees the U.S. launch being "imminent," pending the rescheduling, and said it will be a catalyst for GW Pharmaceuticals given that Epidiolex is the first FDA approved cannabinoid-based therapy. The analyst, who sees the drug being a blockbuster with off label use driving $1.3B in sales by 2025, reiterates his Overweight rating and $197 price target on GW Pharmaceuticals shares.
09/27/18
CANT
09/27/18
NO CHANGE
Target $211
CANT
Overweight
Cantor says Epidiolex DEA rescheduling 'best possible outcome' for GW Pharma
Cantor Fitzgerald analyst Elemer Piros noted that the DEA rescheduled Epidiolex to Schedule V, the lowest ranked class, from being a Schedule I drug, as he expected. He believes this rescheduling classification is "the best possible outcome" for GW Pharmaceuticals and checks off the last box as the company prepares to launch the drug within six weeks. Piros reiterates an Overweight rating and $211 price target on GW Pharmaceuticals shares.
09/28/18
MSCO
09/28/18
NO CHANGE
Target $240
MSCO
Overweight
GW Pharmaceuticals price target raised to $240 from $197 at Morgan Stanley
Morgan Stanley analyst David Lebowitz raised his price target on GW Pharmaceuticals shares to $240 from $197 following the DEA's assignment of Epidiolex to Schedule V, which he said was a better classification than he expected. Stating that the favorable scheduling should enable a strong launch, Lebowitz increased his Epidiolex estimates and maintains an Overweight rating on GW Pharmaceuticals.

TODAY'S FREE FLY STORIES

SCI

Service Corp.

$42.31

-0.42 (-0.98%)

11:17
02/21/19
02/21
11:17
02/21/19
11:17
Hot Stocks
Service Corp. raises quarterly cash dividend 6% to 18c per share »

Service Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Mar

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
02/21/19
02/21
11:17
02/21/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
02/21/19
02/21
11:16
02/21/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
02/21/19
02/21
11:15
02/21/19
11:15
General news
Breaking General news story  »

8-Week Bill Auction to be…

11:15
02/21/19
02/21
11:15
02/21/19
11:15
General news
Breaking General news story  »

4-Week Bill Auction to be…

GS

Goldman Sachs

$197.12

-1.49 (-0.75%)

11:10
02/21/19
02/21
11:10
02/21/19
11:10
Initiation
Goldman Sachs initiated  »

Odeon's Dick Bove…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 03

    Mar

  • 12

    Mar

11:10
02/21/19
02/21
11:10
02/21/19
11:10
General news
Energy Action: NYMEX crude »

Energy Action: NYMEX…

DK

Delek US

$36.95

-0.13 (-0.35%)

11:10
02/21/19
02/21
11:10
02/21/19
11:10
Options
Delek US draws upside call buyers as shares slip off early highs »

Delek US draws upside…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:10
02/21/19
02/21
11:10
02/21/19
11:10
General news
Existing home sales fell 1.2% in January to 4.99 M, a 3-year low »

Existing home sales fell…

11:08
02/21/19
02/21
11:08
02/21/19
11:08
General news
3-Month Bill Announcement CUSIP Number data reported »

3-Month Bill Announcement…

MNST

Monster Beverage

$58.64

-0.07 (-0.12%)

11:07
02/21/19
02/21
11:07
02/21/19
11:07
Options
Monster Beverage option volume spikes to 3X daily average amid active trading »

Monster Beverage option…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

LIVN

LivaNova

$98.56

-1.32 (-1.32%)

11:07
02/21/19
02/21
11:07
02/21/19
11:07
Recommendations
LivaNova analyst commentary  »

Piper says Japanese…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 06

    Mar

  • 07

    May

  • 08

    May

  • 09

    May

UBCP

United Bancorp

$10.95

(0.00%)

11:04
02/21/19
02/21
11:04
02/21/19
11:04
Hot Stocks
United Bancorp raises quarterly cash dividend to 13.25c per share »

The Board of Directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LIVN

LivaNova

$98.59

-1.29 (-1.29%)

11:03
02/21/19
02/21
11:03
02/21/19
11:03
Hot Stocks
LivaNova announces national reimbursement in Japan for Perceval valve for AVD »

LivaNova announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 06

    Mar

  • 07

    May

  • 08

    May

  • 09

    May

KO

Coca-Cola

$45.48

0.36 (0.80%)

11:03
02/21/19
02/21
11:03
02/21/19
11:03
Hot Stocks
Coca-Cola announces new share repurchase program for up to 150M shares »

The Coca-Cola board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 03

    Mar

KO

Coca-Cola

$45.49

0.37 (0.82%)

11:02
02/21/19
02/21
11:02
02/21/19
11:02
Hot Stocks
Coca-Cola raises quarterly dividend to 40c per share from 39c per share »

The Coca-Cola board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 03

    Mar

11:00
02/21/19
02/21
11:00
02/21/19
11:00
General news
EIA natural gas storage change for week ending February 15 »

Earlier, gas inventories…

11:00
02/21/19
02/21
11:00
02/21/19
11:00
General news
Crude inventories for week of February 15 »

Crude oil inventories…

KR

Kroger

$28.82

0.07 (0.24%)

11:00
02/21/19
02/21
11:00
02/21/19
11:00
Options
One-day call buyers in Kroger »

One-day call buyers in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

  • 07

    Mar

UAA

Under Armour

$21.26

-0.02 (-0.09%)

, UA

Under Armour

$19.22

0.025 (0.13%)

10:52
02/21/19
02/21
10:52
02/21/19
10:52
Periodicals
Under Armour CEO questioned by board about ties with MSNBC anchor, WSJ says »

A number of current and…

UAA

Under Armour

$21.26

-0.02 (-0.09%)

UA

Under Armour

$19.22

0.025 (0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

  • 06

    Mar

10:50
02/21/19
02/21
10:50
02/21/19
10:50
General news
U.S. corporate bond update: issuance continues apace today »

U.S. corporate bond…

COUP

Coupa Software

$92.39

-1.36 (-1.45%)

10:50
02/21/19
02/21
10:50
02/21/19
10:50
Options
Short-term hedge opened in Coupa Software »

Short-term hedge opened…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Mar

  • 11

    Mar

  • 12

    Mar

  • 12

    Mar

10:50
02/21/19
02/21
10:50
02/21/19
10:50
General news
FX Action: USD-JPY »

FX Action: USD-JPY has…

OHRP

Ohr Pharmaceutical

$2.01

(0.00%)

10:47
02/21/19
02/21
10:47
02/21/19
10:47
Hot Stocks
Ohr Pharmaceutical regains compliance with Nasdaq listing requirements »

Ohr Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMDZ

Immune Design

$5.81

4.385 (307.72%)

, MRK

Merck

$79.79

0.35 (0.44%)

10:46
02/21/19
02/21
10:46
02/21/19
10:46
Downgrade
Immune Design, Merck rating change  »

Immune Design downgraded…

IMDZ

Immune Design

$5.81

4.385 (307.72%)

MRK

Merck

$79.79

0.35 (0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Mar

  • 11

    Apr

  • 18

    May

  • 17

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.